Cotellic(Cobimetinib) Side Effects

Cobimetinib is associated with diverse, often grade-dependent toxicities requiring proactive management.

Common and Severe Adverse Reactions

Melanoma cohort: Most frequent AEs (≥20%) included diarrhea (60%), photosensitivity (46%), nausea (41%), pyrexia (28%), and vomiting (24%). Grade 3–4 lab abnormalities included elevated GGT (21%), CPK (14%), and lymphopenia (10%). Histiocytic neoplasms: Common AEs included acneiform dermatitis (65%), diarrhea (62%), infections (62%), and fatigue (42%). Severe AEs (grade ≥3) included CPK elevation (27%), hyponatremia (18%), and decreased LVEF (12%). Class-specific risks included hemorrhage (13% melanoma; 19% histiocytosis), retinopathy (26% melanoma), and rhabdomyolysis (3.6% melanoma). Dose interruptions/reductions occurred in 55% of melanoma patients. Fatalities from AEs were rare but linked to hepatotoxicity or cardiomyopathy.

Cobimetinib(Cotellic)
Cotellic is indicated for the treatment of adult patients with melanoma harboring the BRAF V600E or V600K mutation.
RELATED ARTICLES
How effective is cobimetinib in treatment?

Cobimetinib is an oral anticancer drug belonging to the class of MEK inhibitors. It mainly works by inhibiting the...

Wednesday, August 20th, 2025, 13:30
How is the therapeutic effect of cobimetinib?

Cobimetinib is suitable for the treatment of unresectable or metastatic melanoma with BRAFV600E or V600K mutations...

Thursday, July 10th, 2025, 16:12
/ 1
2 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved